About Alzamend Neuro, Inc.


What is Alzheimer's disease?

Alzamend Neuro is preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. With our two current and future product candidates, we aim to bring treatments or cures to market at a reasonable cost as quickly as possible. Far too many individuals – patients and caregivers – suffer from the burden created by these devastating, and often fatal, diseases. Our primary target, Alzheimer’s disease, was among the most-feared diseases (second only to cancer) among Americans, according to a 2011 survey by the Harvard School of Public Health. Alzheimer’s is also the sixth leading cause of death in the United States according to a 2021 report from the Alzheimer’s Association, a nonprofit that funds research. Existing Alzheimer’s treatments only temporarily relieve symptoms but do not slow or halt the underlying worsening of the disease, which currently affects roughly 6.2 million Americans and that number is expected to grow to 13 million individuals by 2050. Alzheimer’s also impacts more than 11 million Americans who provide an estimated 15.3 billion hours of unpaid care per year, valued at $257 billion, according to data provided by the Alzheimer’s Association. In 2021, the estimated healthcare costs for treating individuals with Alzheimer’s in the United States will be $355 billion, including $239 billion in Medicare and Medicaid payments. These costs could rise to as high as $1.1 trillion per year by 2050 if no permanent treatment or cure for Alzheimer’s is found, the Alzheimer’s Association reported.


  • The number of Americans projected to be living with Alzheimer’s disease by the year 2050

  • The number of Americans projected currently living with Alzheimer’s disease in 2021

  • The number of Americans that provide unpaid care for people with Alzheimer’s or other Dementias

  • Leading cause of death in the U.S.

  • The estimated number of seniors that will die with Alzheimer’s disease or another dementia

  • Leading cause of death for Americans age 65 and older & Leading cause of disability and poor health for Americans

  • The estimated cost in 2021 of Alzheimer’s disease to the United States.

  • The estimated value of unpaid care to Alzheimer’s patients by their caregivers including family and friends

  • The estimated cost of by 2050 of Alzheimer’s disease to the United States if no treatment or cure is found

  • The estimated number of Americans age 65 and over that are afflicted in 2021 with Alzheimer’s disease